Compositions and methods that inhibit il-23 signaling
US-2024425579-A1 · Dec 26, 2024 · US
Methods of using anti-IL13 human antibodies
US8992916B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8992916-B2 |
| Application number | US-201314044314-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 2, 2013 |
| Priority date | Oct 21, 2005 |
| Publication date | Mar 31, 2015 |
| Grant date | Mar 31, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating atopic dermatitis, comprising administering to a subject in need thereof an effective amount of a composition comprising an antibody, or functional fragment thereof, that binds human interleukin-13, wherein said antibody or a functional fragment thereof comprises H-CDR1, H-CDR2 and H-CDR3 selected from (i)-(ii): (i) SEQ ID NO: 6, SEQ ID NO: 8 and SEQ ID NO: 9, respectively; and (ii) SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 10,…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8992916B2 cover?
- The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
- Who is the assignee on this patent?
- Campbell Emma Michelle, Parveen Sofia, Buechler Joe, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/244. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).